Primary Open-Angle Glaucoma (POAG) is a potentially blinding disease if left untreated. As medical professionals, it’s vital that we have a sound understanding of the diagnosis, treatment and prevention of the condition. In this article, we will discuss everything you need to know about POAG for medical professionals. From the causes and risk factors to the symptoms, diagnosis and treatments available; armed with this knowledge, you can give your patients an accurate medical assessment and provide them with the best possible care.
Primary open-angle glaucoma (POAG), also known as primary angle-closure glaucoma, is the most common type of glaucoma. It is a chronic, degenerative eye disease that damages the optic nerve and can lead to vision loss. POAG usually affects both eyes, but one eye may be more affected than the other. The exact cause of POAG is unknown, but it is thought to be associated with a combination of risk factors, including increased intraocular pressure (IOP), age, family history and certain medical conditions. POAG typically progresses slowly and painlessly over several years. In some cases, however, it can progress quickly and lead to vision loss in a matter of months or even weeks. There is no cure for POAG, but it can be controlled with medical treatment. The goal of treatment is to reduce IOP and slow or stop the progression of the disease. Treatment typically involves the use of medications (eye drops) and/or surgery.
There are a number of risk factors for POAG some of which are modifiable and some of which are not. Modifiable risk factors include high intraocular pressure, diabetes and a history of glaucoma in a first-degree relative. Non-modifiable risk factors include age, African ancestry and advanced age. POAG is more common in older adults and the risk of developing the condition increases with age. African Americans are at a higher risk for POAG than other racial groups and people with a family history of glaucoma are also at an increased risk. High intraocular pressure is the most important modifiable risk factor for POAG. IOP can be controlled through medications or surgery and reducing IOP can help to slow the progression of glaucoma or even reverse it in some cases. Diabetes is another modifiable risk factor for POAG; people with diabetes are more likely to develop the condition than those who do not have diabetes.
The most common signs and symptoms of primary open-angle glaucoma (POAG) are slowly progressive, painless loss of peripheral vision and decreased visual acuity. Other signs and symptoms may include: Halos around lights, Tunnel vision, Headaches, Eye pain, Nausea or vomiting.
A comprehensive eye examination is necessary to properly diagnose POAG. This includes testing of visual acuity, intraocular pressure (IOP) and the appearance of the optic nerve head. Further testing may be indicated based on the findings of the initial examination. These tests may include evaluation of the drainage angle of the eye, measurement of central corneal thickness and assessment of retinal nerve fiber layer integrity.
There are several different treatment options for primary open-angle glaucoma (POAG). The most common approach is to lower the intraocular pressure (IOP) with medication, surgery or a combination of both. Medications for POAG can be either topical (eye drops) or systemic (pills taken by mouth). The most common type of eye drop used to treat POAG is a beta blocker, which works by decreasing the production of aqueous humor, the clear fluid that fills the front part of the eye. Other types of eye drops that may be used include prostaglandin analogs and α2-adrenergic agonists which help to decrease IOP by increasing outflow of aqueous humor. Systemic medications used to treat POAG include carbonic anhydrase inhibitors and oral β-blockers. These medications can have side effects including fatigue, depression, gastrointestinal upset and dizziness. Surgery for POAG is typically reserved for cases where medications are not effective in lowering IOP. The two most common types of surgery are trabeculectomy and laser trabeculoplasty. Trabeculectomy involves creating a new channel for fluid to drain from the eye, while laser trabeculoplasty uses a laser to improve drainage through the existing channels. Both procedures carry a risk of complications including infection, bleeding and retinal detachment.
There is no known way to prevent primary open-angle glaucoma (POAG). However, early detection and treatment of the disease is essential to preventing vision loss.
We hope this article has provided medical professionals with a better understanding of POAG and its different treatment options. We have discussed the various causes, risk factors, signs and symptoms as well as ways in which this condition can be managed. With earlier diagnosis and more effective treatments available today it is possible to successfully manage primary open-angle glaucoma. It is important for medical professionals to remain up-to-date on the latest research and developments so that they can provide their patients with optimal care.
1.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
2.
Error on the MGUS-Autoimmune Disease Association.
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
5.
Unified Neuro/Psych Residency Program: New Proposal.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
The Growing Challenge of Haematological Malignancies in Older Adults
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation